BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33104303)

  • 1. Histomolecular features of high-grade endometrial cancers.
    Morotti M; Soleymani Majd H; Casarin J; Alazzam M; Damato S
    Minerva Med; 2021 Feb; 112(1):20-30. PubMed ID: 33104303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
    Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
    Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists.
    Rabban JT; Gilks CB; Malpica A; Matias-Guiu X; Mittal K; Mutter GL; Oliva E; Parkash V; Ronnett BM; Staats P; Stewart CJR; McCluggage WG
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S25-S39. PubMed ID: 30550482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
    Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
    Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
    Prueksaritanond N; Chantape W
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the apparent diffusion coefficient differentiate the grade of endometrioid adenocarcinoma and the histological subtype of endometrial cancer?
    Yan B; Zhao T; Liang X; Niu C; Ding C
    Acta Radiol; 2018 Mar; 59(3):363-370. PubMed ID: 28696169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
    Jones NL; Xiu J; Chatterjee-Paer S; Buckley de Meritens A; Burke WM; Tergas AI; Wright JD; Hou JY
    Int J Cancer; 2017 Mar; 140(6):1396-1404. PubMed ID: 27905110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transtubal spread of endometrial carcinoma: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis.
    Stewart CJ; Doherty DA; Havlat M; Koay MH; Leung YC; Naran A; O'Brien D; Ruba S; Salfinger S; Tan J
    Pathology; 2013 Jun; 45(4):382-7. PubMed ID: 23635815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.
    Tung HJ; Wu RC; Lin CY; Lai CH
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome.
    Di Cello A; Rania E; Zuccalà V; Venturella R; Mocciaro R; Zullo F; Morelli M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():153-60. PubMed ID: 26409060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial carcinoma recurring as carcinosarcoma: report of two cases.
    Ferrandina G; Zannoni GF; Martinelli E; Vellone V; Prisco MG; Scambia G
    Pathol Res Pract; 2007; 203(9):677-81. PubMed ID: 17646054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
    Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
    Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial carcinosarcoma.
    Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Caruso G; Enomoto T; Takehara K; Denys H; Lorusso D; Coleman R; Vaughan MM; Takano M; Provencher DM; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Kim JW; Candido Dos Reis FJ; Ramirez PT; Mariani A; Leitao M; Makker V; Abu-Rustum NR; Vergote I; Zannoni G; Tan D; McCormack M; Paolini B; Bini M; Raspagliesi F; Benedetti Panici P; Di Donato V; Muzii L; Colombo N; Pignata S; Scambia G; Monk BJ
    Int J Gynecol Cancer; 2023 Feb; 33(2):147-174. PubMed ID: 36585027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
    Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
    Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.